Clinicopathologic prognostic markers of survival: An analysis of 259 patients with malignant melanoma ≥1 mm

Tumor Biology

Volumn 31, Issue 1, 2010, Pages 8-15

  Egberts, Friederike ^a   Momkvist, A ^a   Egberts, J H ^a   Kaehler, K C ^a   Weichenthal, M ^a   Hauschild, A ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Melanoma; Metastasis; Prognosis; Sentinel node; Ulceration

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR VOLUME; ULCER;

EID: 77951023386     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-009-0002-3     Document Type: Article

References (23)

1. Morton DL, Wen DR, Foshag LJ, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol. 1993;11:1751-1756
2. Medalie N, Ackerman AB. Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now. Br J Dermatol. 2004;151:298-307.
3. Mohrle M, Schippert W, Rassner G, Garbe C, Breuninger H. Is sentinel lymph node biopsy of therapeutic relevance for melanoma? Dermatology. 2004;209:5-13.
4. Mohrle M, Breuninger H. Sentinel node biopsy. What are the facts? Hautarzt. 2005;56:441-447
5. Perrott RE, Glass LF, Reintgen DS, Fenske NA. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol. 2003;49:567-88. quiz 589-592.
6. Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG, et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol. 2002;146:7-17.
7. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317
8. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-983
9. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648
10. van Akkooi AC, de Wilt JH, Verhoef C, Graveland WJ, van Geel AN, Kliffen M, et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer. 2006;42:372-380
11. Yee VS, Thompson JF, McKinnon JG, Scolyer RA, Li LX, McCarthy WH, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12:429-439
12. Roka F, Kittler H, Cauzig P, Hoeller C, Hinterhuber G, Wolff K, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer. 2005;92:662-667
13. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003;4:748-759
14. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et al. Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res. 2008;18:61-67
15. Thomas JM, Clark MA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol. 2004;30:686-691
16. Kretschmer L, Hilgers R, Mohrle M, Balda BR, Breuninger H, Konz B, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer. 2004;40:212-218
17. Twomey P. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in mslt-1, an international multicenter trial. Ann Surg. 2007;245:156-157
18. Morton DL, Cochran AJ, Thompson JF. Authors' response to a letter to the editor re: sentinel node biopsy for early-stage melanoma. Ann Surg. 2007;245:828-829
19. Thomas JM. Time to re-evaluate sentinel node biopsy in melanoma post-multicenter selective lymphadenectomy trial. J Clin Oncol. 2005;23:9443-9444
20. van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol. 2006;17:1578-1585.
21. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117-126
22. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer. 1999;85:2391-2399
23. Zogakis TG, Essner R, Wang HJ, Foshag LJ, Morton DL. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol. 2007;14:1604-1611